Product Details
Product Details
Product Specification
| Host | Human |
| Stability & Storage | -80℃ |
Background
The kit is based on homogeneous time-resolved fluorescence technology (TR-FRET) technology,which is used to assess the molecular-mediated interaction between the KRAS[G12C] and BRAF. This method provides a high-throughput approach to detect the small molecules capable of mediating the interaction between the KRAS[G12C] and BRAF simply and rapidly.
As shown in the figure below, the interaction between KRAS[G12C] and BRAF was detected by an Eu-labeled anti-Tag1 antibody (TR-FRET donor) and an Ac-labeled anti-Tag2 antibody (TR-FRET receptor). The donor antibody is in close proximity to the receptor antibody. Excitation of the donor antibody triggers fluorescence resonance energy transfer (FRET) to the receptor antibody, resulting in specific emission of a signal at a wavelength of 665 nm from the receptor antibody. And the molecular adhesive Daraxonrasib mediates the interaction between KRAS[G12C] and CypA, which competed with BRAF. Resulting the specific emission of a signal at a wavelength of 665 nm from the receptor antibody decreased. This decrease of specific signal is proportional to the degree of interaction between Daraxonrasib, KRAS[G12C] and CypA. This homogeneous assay is simple to perform and requires no washing steps.

Components
【Composition and Storage Conditions】
Composition |
concentration |
100T |
500T |
2500T |
10000T |
Storage |
Tag1-KRAS[G12C] protein |
100× |
5μL |
20μL |
100μL |
400μL |
-80℃ |
Tag2-BRAF protein |
50× |
10μL |
50μL |
250μL |
1000μL |
-80℃ |
Daraxonrasib |
1mM |
5μL |
10μL |
50μL |
200μL |
-80℃ |
CypA protein |
80× |
5μL |
25μL |
125μL |
500μL |
-80℃ |
Anti-Tag1 Eu antibody |
50× |
5μL |
25μL |
125μL |
500μL |
-80℃ |
Anti-Tag2 Ac antibody |
12.5× |
20μL |
100μL |
500μL |
2000μL |
-80℃ |
Detection buffer |
10× |
400μL |
2mL |
10mL |
40mL |
-80℃ |
Note: Aliquot into appropriate volumes, store at the recommended temperature and avoid repeated freeze-thaw cycle.
Protocol
1、Reagent Preparation
1.1 Compositions equilibration
Before use, equilibrate all reagents at room temperature (allow at least 30 minutes for temperature equilibration). For the 384-well plate assay, use 20 μL of reaction mixture (the reagent quantities are listed in the table below). Calculate the required volume prior to preparation accordingly. The following preparation steps are provided for reference only, using a 500-well plate as an example.
Table 1. Reagent Preparation
Composition |
Configuration |
μL/well |
Detection buffer |
Add 2 mL of 10× Detection buffer to 18 mL of deionized water, dilute to 1× Detection , and mix thoroughly for later use. |
- |
Tag1-KRAS[G12C] protein |
Take 20 μL of the 100× Tag1-KRAS[G12C] protein stock solution, add 1.98 mL of 1× Detection buffer to dilute it to 1× concentration, and mix thoroughly for later use. |
4 |
Tag2-BRAF protein |
Take 50 μL of the 50× Tag2-BRAF protein stock solution, add 2.45 mL of 1× Detection buffer to dilute it to 1× concentration, and mix thoroughly for later use. |
5 |
CypA protein |
Take 25 μL of the 80× CypA protein stock solution, add 1.975 mL of 1× Detection buffer to dilute it to 1× concentration, and mix thoroughly for later use. |
4 |
Antibody Mix |
Take 25 μL of the 50× Eu-anti-Tag1 stock solution, add 1225 μL of 1× Detection buffer to dilute to 1.25 mL, and mix thoroughly; take 100 μL of the 12.5× Ac-anti-Tag2 stock solution, add 1150 μL of 1× Detection buffer to dilute to1.25 mL, and mix thoroughly; combine the two solutions in a 1:1 ratio to obtain the Antibody Mix. |
5 |
1.2 Gradient dilution of the sample
Daraxonrasib as an example, the dilution solution is 1× Detection buffer. To minimize interference from matrix effects, it is recommended to use a solution with the same matrix composition as the sample being tested; additionally, the sample concentration should be adjusted according to its actual situation.
Table 2. Daraxonrasib gradient dilution(Adjust according to the actual situation)
Daraxonrasib final concentration(nM) |
Daraxonrasib preparation concentration(nM) |
Dilution |
|
① |
2000 |
20000 |
1μL 1mM Daraxonrasib +49μL 1× Detection buffer |
② |
800.00 |
8000.00 |
20μL ① +30μL 1× Detection buffer |
③ |
320.00 |
3200.00 |
20μL ② +30μL 1× Detection buffer |
④ |
128.00 |
1280.00 |
20μL ③ +30μL 1× Detection buffer |
⑤ |
51.20 |
512.00 |
20μL ④ +30μL 1× Detection buffer |
⑥ |
20.48 |
204.80 |
20μL ⑤ +30μL 1× Detection buffer |
⑦ |
8.19 |
81.92 |
20μL ⑥ +30μL 1× Detection buffer |
⑧ |
3.28 |
32.77 |
20μL ⑦+30μL 1× Detection buffer |
⑨ |
1.31 |
13.11 |
20μL ⑧+30μL 1× Detection buffer |
⑩ |
0.52 |
5.24 |
20μL ⑨+30μL 1× Detection buffer |
⑪ |
0.21 |
2.10 |
20μL ⑩+30μL 1× Detection buffer |
Blank |
0 |
0 |
30μL 1× Detection buffer |
2、Sample and control
2.1 Sample:Add 4 μL of Tag1-KRAS[G12C] protein working solution, 4 μL of CypA protein working solution, 2 μL of the gradient-diluted sample, incubate at room temperature for 10min,5μL Tag2-BRAF protein, and 5 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.2 Daraxonrasib : Add 4 μL of Tag1-KRAS[G12C] protein working solution, 4 μL of CypA protein working solution, 2 μL of the gradient-diluted Daraxonrasib, incubate at room temperature for 10min,5μL Tag2-BRAF protein, and 5 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.3 Blank:Add 4 μL of Tag1-KRAS[G12C] protein working solution, 4 μL of CypA protein working solution, 2 μL of 1× Detection buffer, incubate at room temperature for 10min,5μL Tag2-BRAF protein, and 5 μL of the mixed Antibody Mix sequentially into the 384-well plate.
2.4 Negative control: 15μL Detection buffer, and 5 μL of the mixed Antibody Mix sequentially into the 384-well plate.
After adding all samples, centrifuge, seal with a cover membrane, and incubate at room temperature for 1 hours.
Table 3. Sample and control spotting process
Daraxonrasib |
Sample |
Blank |
Negative control (NC) |
|
2μL gradient-diluted Daraxonrasib |
2μL gradient-diluted sample |
2μL 1× Detection buffer |
15μL 1× Detection buffer and 5μL Antibody Mix |
4μL Tag1-KRAS[G12C] protein | |||
4μL CypA protein | |||
Incubate at room temperature for 10min; | |||
5μL Tag2-BRAF protein | |||
5μL Antibody Mix | |||
Seal the plate wells with a sealing film and incubate at room temperature for 1hours. | |||
3、Read Data
The detection was performed on a TR-FRET microplate reader. The excitation wavelength was 320/340 nm, and the emission wavelengths at 620 nm and 665 nm were detected.
【DATA REDUCTION 】
1) Ratio:
Ratio = (665/620) ×10000
2) Net signal:
Net signal = (Std-NC)/NC×100
Std:the ratio of sample and control
NC: the ratio of negative control
3) CV(%):
CV(%)= Standard Deviation/Mean Ratio × 100%
【Data Example】
The following data cannot replace experimental results obtained in experiments; they are provided solely for illustrative purposes, and outcomes may vary depending on the plate reader used.

Note: Recommended microplate (384-well plate, white, shallow wells).
![UniOne® TR-FRET Human KRAS[G12C]/CYPA/BRAF Quaternary Binding Kit](http://www.antbioinc.com/cdn/shop/files/AntBioImage_d07b718d-3883-4b83-a3af-cc16a6b22084.png?v=1793599246&width=1445)